Overview
- Insmed reported that its Phase 2b CEDAR trial in hidradenitis suppurativa failed all efficacy endpoints for brensocatib.
- The company will discontinue development of brensocatib for HS and plans to present the full dataset at a future medical congress.
- By Week 16, abscess and inflammatory nodule counts fell 45.5% on 10 mg and 40.3% on 40 mg of brensocatib, compared with a 57.1% drop on placebo.
- Safety findings showed no new signals, with treatment‑emergent adverse events in 55.4% (10 mg), 42.9% (40 mg), and 45.7% (placebo) of participants and serious events in 4.1%, 1.4%, and 1.4%, respectively.
- Analysts said the outcome was not surprising given HS trials often see high placebo response rates, and they noted recent positive results for Insmed’s Arikayce program that help frame investor reaction.